The search for exceptional responders in tumor sequencing databases

The Washington Post has taken a look at how hospitals are using genetic tumor databases to find exceptional responders to cancer drugs. Such patients, the handful in a large trial who respond far better to a treatment than the rest, have always existed but researchers lacked the tools to learn why they were outliers. Tumor sequencing has provided the tools and the Post featured profiles of several people whose care has improved because of the approach. The challenge now is to see whether the discoveries can be scaled to benefit more patients. Feature (sub. req.)

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.